Syndicated Content about Biotechnology, Pharmaceutical and Healthcare

22:46 EDT 22nd May 2015 | BioPortfolio

Latest global life science, pharmaceutical and healthcare news syndicated from over 50 publishers. 

Showing News Articles 1–25 of 230,000+

Friday 22nd May 2015

Prospects for the development of epigenetic drugs for CNS conditions

Epigenetic mechanisms of gene regulation have an important role in brain development, and evidence is accumulating that some neurological, psychiatric and behavioural disorders can be triggered or maintained by epigenetic means. In this Perspective a...

Malaria medicines: a glass half full?

Despite considerable advances in malaria medicines in the past 20 years, the global burden of malaria remains substantial. Moreover, continued emergence of drug resistance ensures that new antimalarials will be needed in the near future. Wells and co...

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens

Although natural killer (NK) cells can induce immune responses against malignancies, their therapeutic potential in the clinic is largely unexplored. In this Review, Childs and Carlsten discuss recent insights into NK cell biology and how these can b...

Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?

Deal watch: Panning for gold: sourcing pharmaceutical innovation

Drug development for airway diseases: looking forward

Advancing drug development for airway diseases beyond the established mechanisms and symptomatic therapies requires redefining the classifications of airway diseases, considering systemic manifestations, developing new tools and encouraging collabora...

Court: Actavis' Namenda hard switch 'coercion,' 'anticompetitive'

The case could have broad implications for drug makers that seek to market improved versions of their prescription medications.

Perforin and granzymes: function, dysfunction and human pathology

Cytotoxic lymphocytes recognize virus-infected and transformed cells and kill them by apoptosis. Recent studies on the structural and cellular biology of the key mediators of this cytotoxicity — perforin and granzymes — have advanced our understa...

Lymph node fibroblastic reticular cells in health and disease

Fibroblastic reticular cells — which are immunologically specialized myofibroblasts of mesenchymal origin — create a network within lymph nodes that is essential for immunological health through interactions with B cells, T cells, dendritic cells...

T cells: Role reversal

T helper 17 (TH17) cells transdifferentiate into T regulatory type 1 (TR1) cells and contribute to the resolution of inflammation in mice.

Court: Actavis' Namenda forced switch 'coercion,' 'anticompetitive'

The case could have broad implications for drug makers that seek to market improved versions of their prescription medications.

Amarantus selects Chiltern for Phase IIb study

Neurologically-focused biotech Amarantus BioScience has entered into a clinical trial agreement with CRO Chiltern to manage the clinical research and monitoring program services for the Phase IIb study of eltoprazine in Parkinson’s disease levodopa-induced dyskinesia (PD-LID).

inVentiv expands NIS services to help stem confusion on new EU trials regulation

inVentiv Health has expanded its compliance products and services to assist biopharma companies conducting non-interventional studies (NIS). 

House introduces companion bill to offer CROs a share of R&D tax credit

In a House bill that largely mirrors one reintroduced earlier this year in the Senate, CROs (contract research organizations) would be able to capture a share of the R&D tax credit, thereby making the US more competitive with other countries that offer such credits.

Tribute enters US fibrate market

Tribute Pharmaceutical Canada is paying $10m to enter the US fibrate market. The Canadian company is acquiring the US rights to Fibricor (fenofibric acid) from Sum Pharmaceutical Industries. A Tribute subsidiary is paying $5m on the closing of the de...

Amgen dumps brodalumab; AstraZeneca losing a blockbuster?

Uh oh! Safety concerns could derail a psoriasis blockbuster now that one of the developers thinks the risks are too high and ultimately too limiting for the drug to be a success.

Amgen ends partnership with AstraZeneca on psoriasis drug

(Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

UPDATE 2-Amgen ends partnership with AstraZeneca on psoriasis drug

May 22 (Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

UPDATE 1-U.S. bird flu causes egg shortage, emergency measures

* Dutch, French companies seeking U.S. approval to export eggs (Adds details about push to import eggs, background on bird flu)

NeoChord gets $12.6M for mitral valve repair tool that works without stopping the heart

Mitral valve regurgitation is generally fixed with an invasive surgery that requires that the heart is stopped. NeoChord is developing an easier way to do it.

Psychiatry is starting to embrace wearables (video)

Wearables are starting to pop up everywhere in medicine — except, perhaps, actual clinical settings. Even a staid organization like the American Psychiatric Association had some on hand at its 168th annual meeting this week, as this video illustrat...

Amgen ends partnership with AstraZeneca on inflammation drug

(Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in the subjects of a trial.

UPDATE 1-Amgen ends partnership with AstraZeneca on inflammation drug

May 22 (Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in the subjects of a trial.

Smokers more likely to think cancer is a death sentence

(Reuters Health) - Smokers have more pessimistic attitudes about cancer and may be more likely to delay getting screened, according to a new survey from the UK.

Exercise may cut risk of death among elderly men

(Reuters Health) - Elderly men who exercise regularly – even by doing light activities like walking – may be less likely to die than those who are sedentary, a large Norwegian study suggests.


Search BioPortfolio:
Loading
Advertisement
Advertisement